866-997-4948(US-Canada Toll Free)

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017

Published By :

GlobalData

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 1674 Pages

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Breast Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Breast Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Metastatic Breast Cancer 31
Dec 08, 2017: Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer 31
Dec 07, 2017: Prolonged Progression-Free Survival Reinforces Tucatinibs Potential for Patients with Advanced HER2+ Metastatic Breast Cancer 31
Dec 07, 2017: Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium 32
Dec 07, 2017: Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium 33
Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival 33
Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) 34
Dec 05, 2017: Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium 35
Dec 05, 2017: New Scientific Publication Supports Agilvaxs Novel Immunotherapy Development for Metastatic Breast Cancer 36
Dec 04, 2017: Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression 36
Dec 04, 2017: Oncolytics Biotech to Present at the Oncolytic Virotherapy Summit 36
Nov 30, 2017: New and Updated Data for Mercks KEYTRUDA (pembrolizumab) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) 37
Nov 30, 2017: Updated Data on LYNPARZA (olaparib) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) 38
Nov 14, 2017: Daiichi Sankyo to Present Updated DS-8201 Data at SABCS 38
Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium 38
Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer 39
Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 39
Nov 06, 2017: Tyme Announces Encouraging Efficacy and Safety Data from First Human Study of SM-88 in Women with Metastatic Breast Cancer 40
Oct 31, 2017: Dr. Frdric Triebel Presented at the World Immunotherapy Congress 2017 41
Oct 31, 2017: Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain 41
Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 41
Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer 42
Oct 11, 2017: Oncolytics Biotech to Present at the 2017 BIO Investor Forum 42
Oct 06, 2017: Lilly MONARCH 3 Study Published In Journal Of Clinical Oncology Demonstrates Benefit Of Verzenio (Abemaciclib) Plus NSAI In Advanced Breast Cancer 42
Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin 43
Oct 05, 2017: Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program 44
Sep 22, 2017: Eisai Presents Latest Non-Clinical Data On Its First Antibody-Drug Conjugate MORAb-202 At 8th Annual World ADC 44
Clinical Trial Profile Snapshots 45
Appendix 1671
Abbreviations 1671
Definitions 1671
Research Methodology 1672
Secondary Research 1672
About GlobalData 1673
Contact Us 1673
Disclaimer 1673
Source 1674

List of Tables
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2017* 8
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 19
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 19
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
GlobalData Methodology 1672

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *